LivaNova

Vendor Review for Medicaid Vendor Partner Readiness

  • Basic Info
  • EVALUATION

Overall Assessment

Summary

DME company based in England but working to increase footprint in US government funded healthcare. Focuses on cardiac surgery (heart-lung machines) and neuromodulation (vagus nerve stimulation). Will find US based employees under LivaNova, LivaNova Cares and Sorin Group. VNS device initially received mixed reviews from CMS, but may be promising treatment for depression. Now CMS covers VNS for depression nationally (in Medicare program) as part of an approved trial aimed at developing evidence to be used in coverage decisions, reversing a previous non-coverage decision.

Limited experience with Medicaid programs, but expect to be engaged by them as coverage efforts advance. 




Relevant Leadership Experience

Points Possible: 212

Points Earned: 30

click to enlarge

Analyst Notes

Extensive healthcare experience

Limited Medicare and Medicaid experience

Role


President & CEO

Damien McDonald

Click for Bio (self-reported)

President

Paul Buckman

Click for Bio (self-reported)

Operations

Ryan Miller

Click for Bio (self-reported)

Cell

Sven Ukatz

Click for Bio (self-reported)

Cell

John Murphy

Click for Bio (self-reported)

Cell

Sai Yedavelli

Click for Bio (self-reported)

Cell

Thad Huston

Click for Bio (self-reported)

Cell

Douglas Manko

Click for Bio (self-reported)

Product/Services

Bryan Olin

Click for Bio (self-reported)

Cell
Cell
Cell

Brand Perception

Points possible: 95

Points earned: 20

click to enlarge

Analyst Notes

2 lawsuits identified

Healthy/stable culture based on internal reviews

​High brand visibility


Clarity of Value Proposition

Points possible: 60

Points earned: 50

click to enlarge

Analyst Notes

Rate high on all items except use of buzzwords and non-specific language


Scalability 

Points possible: 50

Points earned: 50

click to enlarge

Analyst Notes

High annual revenue

Both operations and product teams rated high experience and high tenure

16% 2 year staffin increase


Funding Model

Publicly traded- NASDAQ: LIVN


--END OF REPORT--

x